AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05585762 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ketone ester
Description: 75 mL chocolate flavored beverage containing 25 g of ketone ester. Half a bottle (12.5 g/day) will be consumed for the first 7 days and a complete bottle (25 g/day) will be consumed for the remaining 77 days.
Study NCT05585762 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Non-ketone placebo
Description: 75 mL chocolate flavored beverage containing 25 g of non-ketogenic fat. Half a bottle (12.5 g/day) will be consumed for the first 7 days and a complete bottle (25 g/day) will be consumed for the remaining 77 days.
Study NCT06327113 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CeFAZolin Injectable Solution
Description: One gram Cefazolin reconstituted in 100 mL 0.9% Sodium Chloride (normal saline)
Study NCT05569655 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tolvaptan
Description: Within 12 hours of admission, subjects were randomly assigned to two groups using the central randomization method. For subjects in group A, tolvaptan (15 mg/d) is added to standard therapy (furosemide:20-40mg/d). The treatment lasts for a total of seven days to assess the efficacy and safety of tolvaptan in the treatment of PAH-induced right heart failure.
Study NCT05569655 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Furosemide
Description: Within 12 hours of admission, traditional standard therapy (furosemide:20-40mg/d) is used for all subjects in our clinical trial. The treatment lasts for a total of seven days.
Study NCT05569655 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Furosemide
Description: Within 12 hours of admission, traditional standard therapy (furosemide:20-40mg/d) is used for all subjects in our clinical trial. The treatment lasts for a total of seven days.
Study NCT06496581 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Standard of Care
Description: ADT, abiraterone and each ARSI (Apalutamide, Darolutamide, Enzalutamide) will be administrated according to the standard of care
Study NCT04869098 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: whey protein
Description: Protein drink containing 30g whey protein isolate powder (dissolved in water) consumed 1-1.5 hr prior to their main evening meal every day for 12 days, No other advice will be given.
Study NCT04869098 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Energy-matched mixed-nutrient placebo drink consumed 1-1.5 hr prior to their main evening meal every day for 12 days. No other advice will be given.
Study NCT05139914 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dapagliflozin
Description: 10 mg/day (in capsule form) of dapagliflozin for 6 weeks
Study NCT05139914 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Dapagliflozin
Description: 10 mg/day (in capsule form) of dapagliflozin for 6 weeks
Study NCT05139914 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo capsule for 6 weeks
Study NCT05139914 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo capsule for 6 weeks
Study NCT06202872 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Gamma (40 Hz) tACS at the precuneus region
Description: 40 Hz tACS applied at a current of 3.2 milliampere peak-to-peak using a NuroStym transcranial electrical stimulation (tES) system of NeuroDevice for four times 12 minutes (48 minutes in total) at the Pz (according to the 10-20 international EEG coordinates)
Study NCT06202872 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham tACS at the precuneus region
Description: Sham tACS applied with no effective stimulation between the ramp-up and ramp-down of the current using a NuroStym tES system of NeuroDevice for four times 12 minutes (48 minutes in total) at the Pz (according to the 10-20 international EEG coordinates)
Study NCT05192824 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Orthokeratology lens
Description: The intervention was according to the design of different optical zone and peripheral reverse curve
Study NCT04730180 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Transcranial Magnetic Simulation
Description: Brain stimulation treatment will be performed using FDA-cleared TMS coils according to their intended use of treatment of medication resistant depression by targeting the dorsolateral prefrontal cortex.
Study NCT04730180 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Mixed reality neuronavigation
Description: Targeting of the dorsolateral prefrontal cortex will be performed with the help of a mixed reality neuronavigation system.
Study NCT04884594 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AAV8-hCocH
Description: 2e12 vg/kg single infusion intravenous
Study NCT04884594 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AAV8-hCocH
Description: 6e12 vg/kg single infusion intravenous
Study NCT04884594 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AAV8-hCocH
Description: 4e12 vg/kg single infusion intravenous
Study NCT05317858 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Blood Brain Barrier Disruption - Oncology
Description: BBB opening via Exablate Type 2 system with microbubble resonators on the day of pembrolizumab infusion to treat brain metastases
Study NCT05317858 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pembrolizumab
Description: Pembrolizumab infusion
Study NCT05317858 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab infusion
Study NCT05740748 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tezepelumab
Description: tezepelumab 210 mg sc q4wks for 20 weeks
Study NCT05740748 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo sc q4wks for 20 weeks
Study NCT04320888 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT, PET/CT, and/or CT/MRI
Study NCT04320888 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI, PET/MRI, and/or CT/MRI
Study NCT04320888 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography
Description: Undergo PET, PET/CT, and/or PET/MRI
Study NCT04320888 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Radionuclide Imaging
Description: Undergo scintigraphy
Study NCT04320888 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Selpercatinib
Description: Given PO
Study NCT04320888 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: X-Ray Imaging
Description: Undergo x-ray imaging
Study NCT05979727 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: RE02
Description: Low, medium or high dose of RE02
Study NCT05979727 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Manitol
Description: Placebo Comparator
Study NCT04947735 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Novel spectacle lens design
Description: Use of single vision, impact resistant spectacle lenses may reduce the rate of progression of juvenile myopia
Study NCT04947735 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Spectacle lenses
Description: Single vision, impact resistant spectacle lenses
Study NCT05845931 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Berberine
Description: A single dose of 1000 mg berberine in two capsules will be administered with 250 ml of still water in the overnight fasting condition. A total of 11 blood samples will be taken at defined time points (baseline, 1; 1.5; 2; 3; 4; 5; 6; 8; 10; 24 h). At each time point, blood will be collected in 2x 7.5 ml tubes for collecting serum and plasma samples to determine berberine concentrations. (Women will undergo the Intervention twice, once in the 1st half and once in the 2nd half of their menstrual cycle.) In addition urine will be collected over the time of 0-10 h after berberine intake and body composition will be measured by bioelectrical impedance analysis (BIA).
Study NCT04392258 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: TSH determination
Description: Determination of serum concentration of thyrotropin (TSH)
Study NCT04392258 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: FT4 determination
Description: Determination of serum free thyroxine (FT4) concentration
Study NCT04392258 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: FT3 determination
Description: Determination of serum free triiodothyronine (FT3) concentration
Study NCT04392258 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: SPINA-GT
Description: Calculation of thyroid's secretory capacity (SPINA-GT)
Study NCT04392258 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: SPINA-GD
Description: Calculation of total deiodinase activity (SPINA-GD)
Study NCT05983523 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PEP07
Description: PEP07 is a potent, highly selective, orally bioavailable small molecule inhibitor of Chk1. PEP07 will be provided as 20 mg and 150 mg strength capsules to be administrated orally. Patients allocated to different dose levels of PEP07 monotherapy will receive either 20 mg or 150 mg oral capsules for 2 consecutive days followed by 5 days treatment off (2-on/5-off) schedule every week, 4 weeks as a treatment cycle.
Study NCT04763447 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Attempt to withdrawal OMA treatment
Description: Patients will be told to stop abruptly (no progressive decrease of the dose) their Omalizumab treatment and they will not be prescribed new OMA. In case of loss of control, pulmonologist can adapt asthma treatment, as in usual care. In that case, OMA can be prescribed for a second line
Study NCT04763447 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Continuation of OMA treatment
Description: Patients will be prescribed the same dosage of Omalizumab than they received before randomization, according to their weight and total circulating IgE levels.~In case of safety concerns or loss of control, pulmonologist can modify the patient treatment regimen of OMA or other co-medications, as in usual care.
Study NCT05332691 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Transapical beating-heart septal myectomy
Description: We have invented a beating-heart myectomy device.Through a minimally invasive intercostal incision, septal myectomy could be accomplished via a transapical access in the beating heart using the device. The whole process of resection is monitored, navigated, and evaluated by real-time transesophageal and transthoracic echocardiography. Left ventricle outlet tract gradient and the grade of mitral regurgitation are evaluated each time after resection. Multiple resections are performed to tailor the muscular resection for sufficient relief of left ventricle outlet tract obstruction and mitral regurgitation, while preventing iatrogenic injuries.
Study NCT05926635 — intervention group
Intervention type: DEVICE
Intervention: ATLAS 2030
Description: sessions of rehabilitation with the ATLAS 2030 exoskeleton twice per week as part of their routine rehabilitation
Study NCT06195865 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: DIEP-flap
Description: Breast reconstruction with a deep inferior epigastric perforator flap
Study NCT06195865 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Implant
Description: Breast reconstruction with an implant-based technique
Study NCT05269563 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Surgical intervention
Description: Pars Plana Vitrectomy for Macular Hole Closure
Study NCT00620581 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Paroxetine
Description: Paroxetine 10mg and 20mg during the luteal phase of the menstrual cycle
Study NCT05877430 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CJRB-101
Description: In Phase 1, one or two capsules of CJRB-101 will be given every day. In Phase 2, the CJRB-101 dose selected from Phase 1 will be given every day.
Study NCT05877430 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab injection
Description: 200 mg given by intravenous (IV) infusion once every 3 weeks
Study NCT06180798 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: cold snare endoscopic mucosal resection (C-EMR)
Description: All procedures will be performed by experienced endoscopists (>3 years of experience/>1000 polypectomies) with the patient in the left lateral position under propofol sedation.~The polyp size will be assessed by boston biopsy forceps (open jaws -7mm) or boston jumbo biopsy forceps (open jaws 10mm) or submucosal injection needle (Olympus (4mm)). A standard snare will be used .~submucosal injection of saline mixed with methylene blue will be used (no epinephrine) followed by resection using snare without using electrocautery in C-EMR group.After polypectomy, the area is inspected for residual polyp using NBI and if present, will be resected using biopsy forceps.~Bleeding will be assessed for 2 mins to decide upon requirement of immediate hemostatic methods in the form of clipping or electrocoagulation.
Study NCT06180798 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Hot snare endoscopic mucosal resection (H-EMR)
Description: All procedures will be performed by experienced endoscopists (>3 years of experience/>1000 polypectomies) with the patient in the left lateral position under propofol sedation.~The polyp size will be assessed by boston biopsy forceps (open jaws -7mm) or boston jumbo biopsy forceps (open jaws 10mm) or submucosal injection needle (Olympus (4mm)). A standard snare will be used.submucosal injection of saline mixed with methylene blue will be used.Using ERBE electrosurgical unit - EndoCut Q mode (effect interval duration) and forced coagulation mode in H-EMR group.~After polypectomy, the area is inspected for residual polyp using NBI and if present, will be resected using biopsy forceps.
Study NCT05753709 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Hand sewn end-to-end anastomosis
Description: Hand sewn end-to-end anastomosis (EE) Holding sutures were taken through a seromuscular bite with PDS (Polydiaxonone) 3-0 or Silk 2-0 RB (Round Bodied needle), one each at the mesenteric and antimesenteric ends of the stoma. A posterior layer of Lembert sutures was taken first. The first bite was taken at the anti-mesenteric end and a knot was applied. A Connell stitch was applied at the corner and then the posterior layer was closed using an inverting interlocking continuous stitch till the mesenteric end. Another Connell stitch was applied here to secure the corner and the suture was continued on to the anterior layer which was then closed in a similar manner using a continuous interlocking stitch. The final bite crossed the initial knot and the final knot was applied. An anterior layer of Lembert sutures was taken to reinforce the anastomotic line.
Study NCT05753709 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Hand sewn side-to-side anastomosis
Description: Hand sewn side-to-side anastomosis (HSSA) Each end of the stoma was closed using either a single layer of inverting interlocking continuous sutures with PDS 3-0 or Silk 2-0 RB, or a Linear Stapling device. The two closed stumps were then brought adjacent to each other in an anti-peristaltic arrangement. A posterior layer of Lembert sutures was applied using Silk 2-0 RB. The bowel wall was incised using electrocautery close to the suture line. The incision was lengthened up to a width of at least 5-6 cm. The posterior and anterior layer was now closed using the same technique as in HS using PDS 3-0. An anterior layer of Lembert sutures was applied. The mesenteric defect was then closed using a superficial interrupted layer of Silk 2-0 RB.
Study NCT05753709 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Stapled side-to-side anastomosis
Description: Stapled side-to-side anastomosis or Functional End-to-end anastomosis (SSSA/FEEA) The two limbs of a Linear Cutter SR55 are placed into the proximal and distal bowel loops of the stoma, facing as far away from the mesenteric border as possible and then fired. If both lumens are of similar size, traction sutures are applied with Silk 2-0 RB at the anterior and posterior termination ends of the staple line. The two ends are pulled away from each other, and a Linear Cutter SR75 is applied just below the edge of the bowel and fired. However, in case of an ileo-colostomy, after the first linear cutter SR55 is fired, the two suture lines are approximated in such a way that they do not get apposed but rather lie adjacent to each other. The lumen is then clamped in SR75 which is then fired.
Study NCT06404775 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mastalgia-oil, tamoxifen placebo
Description: external mastalgia-oil 1 ml/d per breast plus oral tamoxifen placebo 10mg/d for 3 consecutive menstrual cycles
Study NCT06404775 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: mastalgia-oil placebo, tamoxifen
Description: oral tamoxifen 10mg/d plus external mastalgia-oil placebo 1 ml/d per breast for 3 consecutive menstrual cycles
Study NCT06512545 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: second allogeneic stem cell transplantation
Description: 1. Change another donor if possible~2. Conditioning regimen: fludarabine (30mg/m2/day, days -6 to -2 )/cyclophosphamide (1g/m2/day, days -5 to -4)/rabbit antithymocyte globulin (1.5mg/kg/day, days -4 to -2)~3. GVHD prophylaxis: cyclosporine A (concentration 150-250ng/ml), mycophenolate mofetil (0.5g bid -3d to neutrophil engraftment)+anti CD25 monoAb (20mg, +1d, +8d, +15d)
Study NCT06587750 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Multisensory Rehabilitation
Description: CMR targets somatosensory and multisensory and cognitive functions through sensory discrimination exercises.
Study NCT04113382 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CLENPIQ
Description: CLENPIQ consists of sodium picosulfate 10.0 mg + magnesium oxide 3.5 g + citric acid, anhydrous 12.0 g.~Supplied as a pre-mixed, ready-to-drink oral solution in two bottles, each containing 160 mL.
Study NCT05520866 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PrehabPal
Description: Web based application
Study NCT04113382 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: MIRALAX
Description: MIRALAX powder for oral solution, supplied in a 8.3 oz multi-dose bottle containing 238 g of laxative powder (polyethylene glycol \[PEG\] 3350).
Study NCT06674018 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Indole-3-propionic acid
Description: A dosis of either 50 mg IPA, 120 mg IPA or 500 mg IPA (two capsules) will be taken orally, once daily in the morning after an overnight fast for 14 consecutive days.
Study NCT06674018 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Two capsules of placebo will be taken orally, once daily in the morning after an overnight fast for 14 consecutive days.
Study NCT05353985 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-062
Description: TAK-062 tablets.
Study NCT05353985 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Simulated Inadvertent Gluten Exposure (SIGE) Gluten-Bar
Description: SIGE gluten bars.
Study NCT05353985 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Simulated Inadvertent Gluten Exposure (SIGE) Gluten-Bar
Description: SIGE gluten bars.
Study NCT05353985 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: TAK-062 Placebo
Description: TAK-062 placebo-matching tablets.
Study NCT05353985 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Simulated Inadvertent Gluten Exposure (SIGE) Gluten-free Bar
Description: SIGE gluten-free bars.
Study NCT05353985 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Simulated Inadvertent Gluten Exposure (SIGE) Gluten-free Bar
Description: SIGE gluten-free bars.
Study NCT06619561 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vimseltinib
Description: Administered orally
Study NCT06617832 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Active drug for acute migraine treatment
Description: Standard dose of Sumatriptan 100 mg, which is used as an acute treatment for episodic migraine
Study NCT06617832 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oral Tablet
Description: Inactive placebo pill (100 mg) looking like the active drug
Study NCT06624449 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cold debriefing
Description: Manipulation (experimental): The researcher assigned a cold debriefing (after one-day post-simulation) for undergraduate nursing students in the intervention group.
Study NCT06624449 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Hot Debriefing
Description: The control group received a hot debriefing (immediately after the simulation).
Study NCT06683222 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Blood sample
Description: 36 ml of blood in 3 x 7 ml dry tubes, 1 x 5 ml EDTA tube, 1 x 5 ml heparinized tube, 1 x 5 ml anti-protease tube)
Study NCT06683222 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Saliva sample
Description: 5 ml of saliva will be taken.